Publication Name	World Journal of Gastroenterology
Manuscript ID	10132
Country	China

Received	2014-03-15 13:50
Peer-Review Started	2014-03-15 23:07
To Make the First Decision	2014-05-13 20:23
Return for Revision	2014-05-21 08:53
Revised	2014-06-13 00:00
Second Decision	2014-07-11 17:00
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-07-11 17:21
Articles in Press	2014-07-11 17:34
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-07-20 15:52
Typeset the Manuscript	2014-11-01 13:37
Publish the Manuscript Online	2014-11-17 15:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biotechnology & Applied Microbiology
Manuscript Type	Autobiography
Article Title	GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Min Xin, Mu-Xiao Zhong, Gong-Li Yang, Yao Peng, Ya-Li Zhang and Wei Zhu
Funding Agency and Grant Number	Funding Agency Grant Number Guangdong Provincial Science and Technology Projects 2011B050400009 Scientific Research Projects of Hubei Province Education Department B2014055
Corresponding Author	Wei Zhu, PhD, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Avenue, Baiyun District, Guangzhou 510515, Guangdong Province, China. chnz_w@126.com
Key Words	Farnesoid X receptor; Adipokines; Adipokine receptors; 3T3-L1 cells; HepG2 cells; Nonalcoholic fatty liver disease
Core Tip	Our study emphasizes for the first time the effect of GW4064, a synthetic farnesoid X receptor (FXR) agonist, on the expression of adipokines and their receptors, and indicates that the way FXR agonist may act in the progress of nonalcoholic fatty liver disease (NAFLD) is at least partially through regulating the expression of adipokines and their receptors. Therefore, our data provide a further theoretical basis for using an FXR agonist in the therapeutic approach of NAFLD.
Publish Date	2014-11-17 15:12
Citation	Xin XM, Zhong MX, Yang GL, Peng Y, Zhang YL, Zhu W. GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. World J Gastroenterol 2014; 20(42): 15727-15735
URL	http://www.wjgnet.com/1007-9327/full/v20/i42/15727.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i42.15727

Full Article (PDF)	WJG-20-15727.pdf
Full Article (Word)	WJG-20-15727.doc
Manuscript File	10132-Review.doc
Answering Reviewers	10132-Answering reviewers.pdf
Copyright License Agreement	10132-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	10132-Language Certificate.pdf
Peer-review Report	10132-Peer review.pdf
Scientific Misconduct Check	10132-CrossCheck.jpg
Scientific Editor Work List	10132-Scientific editor work list.pdf